Patents
This list is provided in accordance with the patent marking provisions under 35 U.S.C. § 287(a).
The patent process is dynamic and the content of this list and association between products and patents may change due to events including, but not limited to issuance or expiration of patents, licensing, product changes, and other circumstances. The content of this list may be updated from time to time and may not be up to date at the specific time you visit this link. Patent applications may be pending or published and patents may have been issued in the United States and elsewhere which are not identified on this list. This list might not be all inclusive and other products not listed here may be associated with one or more properties in the United States or elsewhere. Absence of any patent from this list does not constitute an admission that such patent does not cover a product.
gammaCore™: nerve stimulator or its use is covered by one or more of the following U.S. patents: 8,612,004; 8,676,330; 8,843,210; 8,874,205; 8,914,122; 8,918,178; 8,948,873; 8,983,628; 9,014,823; 9,020,598; 9,037,247; 9,043,001; 9,067,054; 9,119,953; 9,174,066; 9,327,118; 9,233,246; 9,242,092; 9,333,347; 9,339,653; 9,358,381; 9,358,391; 9,399,134; 9,415,219; 9,566,426; 10,279,163; 10,286,211; 10,363,415; 10,384,059; 10,384,061; 10,441,780, 10,507,325; 10,639,490; 11,297,445; 11,298,535; 11,324,942; 11,389,646; 11,400,288; 11,458,297; 11,517,742; 11,623,078; 11,623,080; 11,779,756; 11,854,695; 11,865,329; 11,944,807; 12,070,593; 12,179,012 and D669,188. Additional U.S. and foreign patents pending.
gammaCore Sapphire™: nerve stimulator or its use is covered by one or more of the following U.S. patents: 8,612,004; 8,676,330; 8,843,210; 8,918,178; 8,948,873; 8,983,628; 9,014,823; 9,020,598; 9,043,001; 9,067,054; 9,174,066; 9,233,246; 9,333,347; 9,339,653; 9,242,092; 9,358,391; 9,415,219; 9,566,426; 10,279,163; 10,286,211; 10,384,059; 10,384,061; 10,441,780; 10,507,325; 10,639,490; 11,297,445; 11,298,535; 11,324,942; 11,389,646; 11,400,288; 11,458,297; 11,517,742; 11,581,090; 11,623,078; 11,623,080; 11,684,778; 11,779,756; 11,854,695; 11,865,329; 11,944,807; 12,070,593, and 12,179,012. Additional U.S. and foreign patents pending.
TAC-STIM™: nerve stimulator or its use is covered by one or more of the following U.S. patents: 8,612,004; 8,948,973; 9,067,054; 9,089,719; 9,174,066; 9,333,347; 9,339,653; 9,566,426; 10,286,211; 10,507,325; 10,639,490; 11,298,535; 11,400,288; 11,623,078; 11,623,080; 11,779,756; 11,854,695; 11,865,329; 11,944,807; 12,070,593 and 12,179,012. Additional U.S. and foreign patents pending.
Truvaga 350™: nerve stimulator or its use is covered by one or more of the following U.S. patents: 8,612,004; 8,874,205; 8,914,122; 8,948,973; 9,037,247; 9,067,054; 9,089,719; 9,119,953; 9,174,066; 9,327,118; 9,333,347; 9,339,653; 9,399,134; 9,358,38; 9,566,426; 10,286,211; 10,363,415; 10,507,325; 10,639,490; 11,298,535; 11,400,288;11,623,078; 11,623,080; 11,779,756; 11,854,695; 11,865,329; 11,944,807; 12,070,593; and 12,179,012. Additional U.S. and foreign patents pending.
Truvaga Plus™: nerve stimulator with mobile software application or its use is covered by one or more of the following U.S. patents: 8,612,004; 8,948,973; 9,067,054; 9,089,719; 9,174,066; 9,333,347; 9,339,653; 9,566,426; 10,286,211; 10,507,325; 10,639,490; 10,874,857; 11,020,591; 11,097,102; 11,197,998; 11,260,225; 11,298,535; 11,400,288; 11,446,491; 11,623,078; 11,623,080; 11,701,515; 11,779,756; 11,854,695; 11,865,329; 11,944,807; 11,944,815; 12,070,593 and 12,179,012. Additional U.S. and foreign patents pending.